Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15290542 | 0.92 | MAPT (0.39) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL14642912 | 0.92 | MAPT (0.39) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL14616553 | 0.90 | MAPT (0.44) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL26551381 | 0.90 | MAPT (0.37) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL18037721 | 0.88 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL17231868 | 0.88 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL12679101 | 0.88 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL18519259 | 0.87 | ALDH1A1 (0.39) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL19733500 | 0.84 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL14616551 | 0.83 | LMNA (0.47) | MAPTALDH1A1SMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546549-B2 | Processes for the convergent synthesis of calicheamicin derivatives | WYETH LLC (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130018179-A1 | PROCESSES FOR THE CONVERGENT SYNTHESIS OF CALICHEAMICIN DERIVATIVES | WYETH LLC (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018179-A1 | PROCESSES FOR THE CONVERGENT SYNTHESIS OF CALICHEAMICIN DERIVATIVES | COASY, CALD1, CROCC | MAPT 3669/4885ALDH1A1 3690/4885SMN1; SMN2 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.